The startup develops a therapy product utilizing genomics and genetic sequencing technologies to enhance the efficacy of tumor treatments through optimized cell therapy strategies. By leveraging bioinformatics and data mining, the company aims to provide personalized and effective therapies for cancer patients, improving treatment outcomes.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often lack precision, leading to off-target effects and suboptimal efficacy. Traditional cell therapies may not be optimized for individual patients, resulting in variable response rates and potential for relapse. A need exists for more personalized and effective approaches to cancer treatment that leverage individual genomic profiles.
Solution
This startup is developing a personalized cell therapy platform that uses genomics and genetic sequencing to optimize cancer treatment strategies. By analyzing a patient's unique genomic data, the platform identifies specific targets and tailors cell therapies to enhance efficacy and minimize off-target effects. The approach leverages bioinformatics and data mining techniques to refine cell therapy design, aiming to improve treatment outcomes and reduce the likelihood of relapse. The company's goal is to translate cutting-edge innovations into curative clinical actions, providing personalized and effective therapies for cancer patients.
Target Audience
The primary target audience includes cancer patients seeking personalized treatment options, as well as oncologists and medical centers specializing in cell therapy and precision medicine.
Features
- Genomic sequencing and analysis to identify patient-specific tumor targets
- Bioinformatics-driven optimization of cell therapy design
- Personalized cell therapies tailored to individual patient profiles